Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Newly presented findings from the NEURO-TTRansform study identified thresholds for meaningful improvement in symptoms and disability, which were exceeded by eplontersen treatment.

Eplontersen Exceeds Established Thresholds for Symptom and Disability Improvement in ATTRv-PN

New findings confirm vutrisiran's long-term safety and efficacy in treating hereditary transthyretin amyloidosis, enhancing patient quality of life.

ATTRv-PN Treatment Vutrisiran Demonstrates Long-Term Efficacy in Open-Label HELIOS-A Extension

Videos

In this initial episode, experts Ari Green, MD, and Paul Tesar, PhD, break down the biological foundation and therapeutic importance of remyelination in multiple sclerosis.

Defining Remyelination in the Context of Multiple Sclerosis

Apnimed's AD109 shows promise in treating obstructive sleep apnea, achieving significant results in a landmark Phase 3 trial, paving the way for FDA approval.

Once-Daily Oral Pill for Obstructive Sleep Apnea Shows Promising Phase 3 Results, Paving Way for FDA Submission

AHN's neuro-oncology program aims to revolutionize brain and spine tumor care with innovative therapies, personalized treatment plans, and advanced research initiatives.

Rewiring Brain and Spine Tumor Care: AHN’s Coordinated, Personalized Approach   

, has been with the team since September 2022. Follow her on Twitter 

The assistant professor of neurology at Robert Wood Johnson Medical School discussed the mission of RCASIA, highlights from its annual retreat, and key takeaways from AAN 2025.

NeuroVoices: Brad Kamitaki, MD, on Aiming to Improve Dementia Care in Asian and Pacific American Communities

The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]

Recognizing Scientific Excellence and Impact in Multiple Sclerosis Research: Bruce Bebo, PhD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

PNS 2025

AAN 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

The Roundtable Discussions video series highlights hot topics and major developments in clinical practice, patient management, neurology education and neuroscience, and the institutional practices that are setting the standard for the field. Each series includes multiple key opinion leaders who offer their collaborative insight and perspectives, put together collaboratively with various institutional and advocacy partners.

1rem

In this roundtable discussion, Ari Green, MD, and Paul Tesar, PhD, delve into the current landscape of remyelination in multiple sclerosis (MS), offering expert perspectives on one of the field’s most pressing therapeutic frontiers. The panel explores how our understanding of remyelination has evolved, the tools used to measure it in human studies, and the challenges of translating early scientific success into clinical progress. The conversation also touches on the impact of aging and disease duration on remyelination potential, highlights novel agents in clinical trials, and debates whether remyelination should be pursued as a standalone strategy or in combination with immunomodulatory therapy. Looking ahead, the experts outline the innovations in imaging, trial design, and therapeutic development that could help close the gap between discovery and clinical application.

Remyelination in Multiple Sclerosis: Where Do We Stand?

In the roundtable series "Advances in SMA Treatments: Insights for Neurologists," experts Diana Bharucha-Goebel, MD, and Bakri Elsheikh, MBBS, FRCP, explore the rapidly evolving landscape of spinal muscular atrophy (SMA) care. Across seven episodes, they cover the latest treatment options, updated best practices, and the growing importance of newborn screening and early diagnosis. The series offers neurologists practical insights on integrating new therapies into clinical practice and highlights the essential role of multidisciplinary care in improving outcomes for patients with SMA.

Advances in SMA Treatments: Insights for Neurologists

In this roundtable discussion, Moein Amin, MD, Marisa McGinley, DO, and Devon Conway, MD,explored key developments in multiple sclerosis (MS) treatment and research. The panelists discussed which sessions in the meeting could have the most immediate impact on clinical practice, as well as the potential for emerging therapies like BTK inhibitors and CAR T-cell therapy to reshape MS treatment. They also delve into the promising applications of AI and machine learning in MS, while addressing the challenges that remain. The conversation further touched on the increasing focus on aging and MS progression, with the experts sharing insights on managing aging-related factors in MS care.

Post ACTRIMS Forum Insights: Key Areas of Expansion in Multiple Sclerosis Research 

"From Criteria to Clarity: MS and its Impact on Vision"

, neurologists Elena Grebenciucova, MD, and Neena Cherayil, MD, dive into the crucial relationship between multiple sclerosis (MS) and the visual system. They explore how ocular symptoms, such as optic neuritis, often serve as early indicators of MS and discuss recent advancements in diagnostic criteria, including the incorporation of optic nerve involvement. The discussion highlights the essential role of neuro-ophthalmologists in MS care, emphasizing their expertise in using advanced diagnostic tools like OCT (optical coherence tomography) and their role in distinguishing MS from other conditions with similar ocular symptoms. The series provides insights into the intersection of MS research, patient care, and the evolving understanding of visual impairments in MS.

From Criteria to Clarity: MS and Its Impact on Vision

In this roundtable discussion, sleep experts Seema Khosla, MD, FCCP, FAASM, Jennifer Martin, PhD, and Karin Johnson, MD, examined the impact of daylight saving time on patients with sleep disorders. They highlighted how the time change often exacerbates sleep difficulties, leading to increased complaints of delayed sleep onset, daytime fatigue, and disrupted sleep patterns. Certain populations are more vulnerable to these effects because of rigid schedules and heightened sensitivity to circadian misalignment. To mitigate these disruptions, clinicians recommended gradual adjustments to sleep schedules, consistent wake times, and strategic light exposure. The discussion also considered whether eliminating the time change would benefit public health.

Clinical Perspectives on Time Changes: Sleep Experts Discuss Health Impacts and Solutions     

In this compelling panel discussion, neurologists Vanessa Hinson, MD, PhD (Medical University of South Carolina), Carlayne Jackson, MD (UT Health San Antonio) and Marie Eugene, DO (University of Connecticut) explore the evolving role of women in neurology. They share insights into empowering women leaders, their unique contributions to neurology departments, and the challenges they’ve faced as women in the medical workforce. The conversation also highlights groundbreaking women-related research, making this series a must-watch for those passionate about advancing diversity and inclusion in medicine.

Elevating Women in Neurology: Perspectives From Empowering Leaders

This series discusses Long COVID's prevalence, noting that one in five Americans and one in ten COVID patients may be affected. It features a panel of experts including Ravindra Ganesh, MD, MBBS, FACP, Dip ABOM, Svetlana Blitshteyn, MD, FAAN, and Monica Verduzco-Gutierrez, MD.

A Deep Dive: Understanding the Neurological Toll of Long COVID

This panel series, featuring renowned experts Kapil Arya, MD; Juan Francisco Vazquez Costa, MD, PhD; and Mary Schroth, offers neurologists an in-depth look into the latest advancements in the diagnosis of spinal muscular atrophy (SMA). Across six comprehensive segments, these leading clinicians and researchers explore the evolving best practices, emerging evidence, and critical updates that impact both clinical care and patient outcomes. The series covers essential topics, including newborn screening protocols, the role of early diagnosis, adult-onset 5q SMA, and the importance of timely treatment access. Tailored for the medical community, this series provides key insights into the future of SMA diagnosis and management.

SMA Diagnosis & Care: New Horizons for Neurologists

Neurologists Benjamin Greenberg, MD, and Jeffrey Bennett, MD, PhD, delved into the complexities of diagnosing and treating MOG antibody-associated disease (MOGAD). The duo share insight about the evolving diagnostic process and the current treatment landscape, emphasizing both pharmacologic and non-pharmacologic approaches. Further, they discussed ongoing research efforts and drug developments aimed at addressing unmet needs in managing this challenging condition.

Entering a New Realm of Treating MOGAD: Insights on Improvements in Diagnosis, Therapeutics, and Emerging Research

John England, MD, FAAN, and Lisa Merlin, MD, cover the ins and outs of the 2024 Association of University Professors of Neurology (AUPN) Annual Meeting, held September 14th in Orlando Florida.

Previewing the 2024 AUPN Annual Meeting

Jeff Cohen, MD; Alycin Magruder, PharmD; and Sarah Anderson, PharmD, discuss the recent introduction of biosimilars into the therapeutic landscape of multiple sclerosis, and the downstream effects for physicians, patients, and payers in this new era of treatment.

Generic and Biosimilar Medications | National MS Society

Ask an MS Expert: Biosimilars and Generics

Guide to Prescription Financial Assistance

The Beginning of the Biosimilars Era in Multiple Sclerosis

Sanford Siegel, Douglas Kerr, MD; and Benjamin Greenberg, MD, comment on several topics related to the treatment of rare neuroimmune disorders, including complexities with distinguishing certain conditions and where research should be dedicated to in the coming years.

History of SRNA and Advances in Rare Neuroimmune Disorders

Robert Griggs, MD; Clifton Gooch, MD; and Henry Kaminski, MD, former presidents of the AUPN, share insight on the changes in neurology and how it is taught, the lessons learned over time, and the future for other neurology department leaders. 